Serial immune function testing to predict clinical disease relapse in patients with solid tumors

Braun, Donald P.; Harris, Jules E.

doi:10.1007/bf00199159

Cited by 7 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the IL-2 production after PHA stimulation in PBMNCs from patients with STCC is not significantly decreased with respect to that found in healthy controls. A similar pattern of abnormal function of the T-cell compartment of peripheral blood has been found in patients with other tumours or with autoimmune diseases (Braun et al, 1983;Mantovani et al, 1987;Gaspar et al, 1988). We have clearly demonstrated that there is a significant enhancement of the proliferative response of PBMNCs to polyclonal mitogens in the STCC patients who were treated prophylactically with intravesical instillations of IFN-a2b and who remained free of tumour recurrence after 1 year of follow-up.…”

Section: Proliferation Studiessupporting

confidence: 86%

Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation

Moltó

Álvarez‐Mon²,

Carballido³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

Summary The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-2b) upon the blastogenic response of PBMNCs from patients with superficial transitional cell carcinoma (STCC) of the bladder to mitogenic signals that interact with surface molecules [phytohaemagglutinin, PHA and anti-CD3 monoclonal antibodies, (MAbs)]. PBMNCs from the patients were studied prior to the transurethral resection (TUR) of the tumour, during the second month of prophylactic intravesical instillation of IFN-M2b and 3 and 6 months after finishing the instillation treatment. The ['H]thymidine uptake of PBMNCs from 17 patients with STCC of the bladder after 5 days of PHA and anti-CD3 MAb stimulus was found to be significantly lower than that of healthy controls (P<0.05). The addition of interleukin 2 (IL-2) to the culture medium did not correct this defective proliferative response to PHA and the anti-CD3 MAb. There were no significant differences between IL-2 production in PBMNCs from STCC patients after stimulation with PHA and in PBMNCs from healthy controls (P>0.05). Patients without evidence of recurrence showed a significantly enhanced proliferative response in PBMNC to PHA and anti-CD3 MAb after intravesical prophylactic treatment with interferon-M2b in the follow-up examinations 3 and 6 months after treatment (P<0.01). However, three patients had evidence of tumour recurrence, and they showed no enhancement of the PBMNC proliferative response to these mitogens in the same examinations. In conclusion, the prophylactic intracavitary treatment of STCC with IFN-M2b may induce a systemic immunomodulatory effect which is associated to the clinical evolution of the disease.

show abstract

Section: Proliferation Studiessupporting

confidence: 86%

Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation

Moltó

Álvarez‐Mon²,

Carballido³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The impairments observed in lymphocytes are often subtle as reflected by variably decreased, but not absent, immune functions and are more pronounced at the tumour site than in the peripheral circulation of patients with cancer. Evidence indicates that the tumour itself exerts these immunosuppressive effects, including decreased monocyte/macrophage functions (Bast and Knapp, 1984) and diminished cellular immunity as manifested by decreased numbers of circulating lymphocytes, their reduced responsiveness to mitogens and by decreased delayed cutaneous hypersensitivity (DTH) observed in patients with high tumour burdens (Braun and Harris, 1983;Brooks and Rees, 1988).…”

mentioning

confidence: 99%

Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients

et al. 2001

View full text Add to dashboard Cite

SummaryIn women with ovarian cancer, suppression of components of the immune system may promote tumour development. Previous studies in ovarian cancer have demonstrated that decreased expression and function of the T-cell receptor (TcR)-associated signal transducing zeta-chain correlates with deficient immune responsiveness of T cells. In this study, sera and ascitic fluids obtained from woman with advanced ovarian cancer were found to suppress the expression of TcR-associated zeta chain. This suppression of zeta chain expression was dose-dependent and was not observed with biologic fluids obtained from healthy women.The factor responsible for the loss of zeta chain was purified from ascites and characterized as a protein with an appropriate molecular weight of 14 kD. Suppression of T-cell TcR-zeta was specific, since neither lck nor ZAP-70 expression was affected, while zeta chain was almost completely suppressed. This selective suppression of TcR-zeta expression by the 14 kD ascites-derived factor was shown to operate at the mRNA level. By defining the mechanism through which this protein modulates TcR-zeta chain levels, it might be possible to ultimately prevent the suppressive influences of the tumour microenvironment and restor immune competence in patients with ovarian carcinoma.

show abstract

Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy

Klein

Steerenberg

Poelma

et al. 1986

Cancer Immunol Immunother

View full text Add to dashboard Cite

Lymphocyte stimulation with Con A and specific immune reactivity to BCG (antibody formation to BCG and DTH reaction to PPD) were determined in BCG-treated, surgically treated and untreated cows with ocular squamous cell carcinoma. In tumor-bearing cows the Con A-induced proliferation of lymphocytes was reduced when compared to healthy controls. This suppression consisted of a reduced blastogenic response to Con A of lymphocytes from tumor-bearing cows, and the presence of a factor in the sera of these animals, as these sera suppressed the blastogenic response of lymphocytes from healthy cows. BCG had only a minor influence on the suppressive activity. Antibodies to BCG were demonstrated in 50% of the BCG-treated animals. The formation of antibodies was not influenced by intradermal injection of PPD of Mycobacterium bovis. Absorption of a BCG antibody containing serum with BOSCC tumor extracts did not reveal the existence of cross reacting antigens between BCG and BOSCC. Pretherapeutic and posttherapeutic Con A reactivity could not be correlated with clinical response. Of the 30 BCG treated cows 29 developed a positive DTH reaction to PPD. Correlation between clinical response and immune reactivity was seen only with regard to the DTH reaction to PPD: this reaction remained positive for a longer period after treatment in animals with a favorable clinical outcome than in nonresponding animals.

show abstract

Serial immune function testing to predict clinical disease relapse in patients with solid tumors

Cited by 7 publications

References 47 publications

Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation

Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation

Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients

Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy

Contact Info

Product

Resources

About